Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma

Malignant pleural mesothelioma (MPM) is a treatment recalcitrant tumor with a poor overall survival (OS). Current approved treatment consists of first line chemotherapy that only modestly increases OS, illustrating the desperate need for other treatment options in MPM. Unfortunately, clinical studie...

Descripción completa

Detalles Bibliográficos
Autores principales: Belderbos, Robert A., Vroman, Heleen, Aerts, Joachim G. J. V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283907/
https://www.ncbi.nlm.nih.gov/pubmed/32582537
http://dx.doi.org/10.3389/fonc.2020.00777

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7283907/
https://www.ncbi.nlm.nih.gov/pubmed/32582537
http://dx.doi.org/10.3389/fonc.2020.00777

Ejemplares similares